Excipients make the difference! Dr. Felicitas Guth Global Technical Service Excipients Pharma Ingredients & Services BASF SE
|
|
- Susanna Fleming
- 6 years ago
- Views:
Transcription
1 Excipients make the difference! Dr. Felicitas Guth Global Technical Service Excipients Pharma Ingredients & Services BASF SE
2 Paradigm shift in pharmaceutical development Traditional medicinal products Trial & error Drug delivery systems Quality by Design Increased functionality and understanding of excipients Excipients make the difference F.Guth PharmSciFair
3 Innovation in excipients Standard excipients used in combination with innovative technologies Co-processed excipients (a combination of two or more excipients designed to physically modify their properties in a manner not achievable by simple physical mixing, and without significant chemical change) Novel excipients (new chemical entities, mostly polymers with a specific functionality) Excipients make the difference F.Guth PharmSciFair
4 Standard excipients & innovative technologies Copovidone in pharmaceutical melt extrusion Excipients make the difference F.Guth PharmSciFair
5 The solubility challenge H Trans, S Trans H Sub,S Sub H Solv, S Solv H S, S S Zimmermann, I.: Pharmazeutische Technologie. Springer Verlag Berlin, Heidelberg, Excipients make the difference F.Guth PharmSciFair
6 Relevant types of solid dispersions Drug crystalline amorphous dissolved Polymer amorphous amorphous amorphous Thermoynamic stability almost stable unstable (kin. Controlled) stable (below satur. solubility) Excipients make the difference F.Guth PharmSciFair
7 Polymers in pharmaceutical melt extrusion Instant release Enteric Sustained release Copovidone* PEG** Povidone PVA-PEG HPMC HPC Poloxamers Amino methacrylate copolymer Methacrylic acid copolymer HPMCAP HPMCAS PVAc PVP/ PVAc EC Ammonio methacrylate copolymer * Kaletra (Actives: Ritornavir & Lopinavir; copovidone matrix) ** Gris-PEG, Novartis (Active: Griseofulvin, PEG matrix) Excipients make the difference F.Guth PharmSciFair
8 Principle of pharmaceutical melt extrusion Die Tempering Cylinder Screw Powder Extrudate Engine Shaping Mixing Melting according to Reitz (2007) Temperature: above T g of polymer ( C) Residence time: variable (0.5 5 min) Excipients make the difference F.Guth PharmSciFair
9 Performance characteristics Long term stability Targeted release profile Glass transition temperature Hygroscopicity Drug + Polymer Melt viscosity Physicochemical properties of active Thermostability of drug & polymer Solution & solubilizing capability Not all relevant parameters may be covered by the standard specification of the excipient! Excipients make the difference F.Guth PharmSciFair
10 Copovidone Copovidone is a copolymer consisting of 6 parts of N-vinylpyrrolidone and 4 parts of vinyl acetate. Pharmacopeia monographs in JPE, Ph.Eur and USP/NF Traditional use: Wet binder and film forming agent CH CH 2 N O CH O C CH 2 O n CH 3 m Excipients make the difference F.Guth PharmSciFair
11 Copovidone in melt extrusion processes Requirements Thermoplastic behavior Copovidone Suitable Tg and melt viscosity Tg: 101 C Good thermal stability between 50 & 180 C Low water content and hygroscopicity to prevent re-crystallization Safety High [or no] solubilization capacity Water content: max. 5% Self affirmed GRAS Excipients make the difference F.Guth PharmSciFair
12 Melt viscosity as a function of temperature Viscosity [Pa s] Kollicoat Kollicoat MAE 100 MAE P Kollidon 30 Kollidon 12 PF Kollidon SR Kollidon VA 64 Kollidon 12 PF Kollidon 30 Kollidon SR Shear stress controlled rotational rheometer (Rheometrics SR5) Plate plate geometry Angular frequency: 1.6 rad/s 100 Kollidon VA Temperature [ C] Excipients make the difference F.Guth PharmSciFair
13 Melt viscosity as a function of shear rate Shear stress controlled rotational rheometer (Rheometrics SR5) Plate plate geometry Temperature: 170 C Viscosity [Pa*s] Kollidon SR Kollicoat MAE 100 P Kollidon VA Kollidon Angular Frequency [rad/s] Excipients make the difference F.Guth PharmSciFair
14 Processes run at high temperatures Hot melt extrusion Steam sterilization C/ min Non aqueous environment Potential reactions: Hydrolysis, oxidation, elimination of water Relatively new process; few approved drug products 121 C/ 2 bar/ 15 min Aqueous environment Potential reactions: Hydrolysis Process well known by excipient users and health authorities Low Probability of significant degradation due to short process times! Excipients make the difference F.Guth PharmSciFair
15 Thermal stability of copovidone Test parameter Requirements Results Powder Results Extrudates Vinyl acetate max. 10mg/kg <10mg/kg < 10mg/kg Vinyl pyrrolidone max. 10mg/kg <2mg/kg < 2mg/kg Acetaldehyde max. 500mg/kg <10mg/kg <10mg/kg Peroxide max. 400mg/kg <20mg/kg <20mg/kg 2-Pyrrolidone max. 0.5g/100g 0.06g/100g 0.06g/100g Saponification value [mg KOH/g] ph-value (10% in Solution) K-value (1% aqueous solution) min. 3.0 max. 7.0 min max Polymers for pharmaceutical melt extrusion.ppt/ Excipients make the difference F.Guth PharmSciFair
16 Thermal stability of copovidone Kollidon VA 64 LOT L0 extruded 160 C Kollidon VA 64 LOT L0 w(log(m)) ,000 10, ,000 1,000,000 10,000,000 M/Da Excipients make the difference F.Guth PharmSciFair
17 Innovation potential & challenges Pharmaceutical melt extrusion with selected thermo-stable polymers proved to be a potent technology to overcome limitations in bioavailability. But: The technology usually involves exposure to higher temperatures and requires excipient doses which significantly exceed the amount in previously approved medicinal products Users and suppliers have to jointly define relevant performance characteristics and evaluate the safety of the excipient Excipients make the difference F.Guth PharmSciFair
18 Novel excipients PEG-PVA Copolymer (Kollicoat IR) Excipients make the difference F.Guth PharmSciFair
19 Desired functionality Target: Cost efficient coating process Good stability and rapid dissolution of the active ingredient Requirements Processing of coating suspensions with a high solid content Flexible and elastic film that dissolves quickly Excipient properties Low viscosity & low surface tension of the polymer solution High solubility & high flexibility of the polymer Excipients make the difference F.Guth PharmSciFair
20 Kollicoat IR - Polymer structure & properties ~ 25 %PEG & ~75% PVA units Mw: ~ The polyvinyl alcohol moiety provides good film-forming properties The polyethylene glycol part acts as an internal plasticizer The polymer quickly dissolves in water, weak acids and bases as well as in diluted ethanol. It is practically insoluble in organic solvents Excipients make the difference F.Guth PharmSciFair
21 Viscosity of aqueous polymer solutions Dynamic viscosity [mpas] Kollicoat IR: 17% PVA: 11% HPMC 603: 10% HPMC 606: 6% Temperature [ C] Equipment: ThermoFisher Scientific, Haake RheoWin 322 Kollicoat IR PVA 5-88 HPMC type 603 HPMC type Excipients make the difference F.Guth PharmSciFair
22 Viscosity of aqueous polymer solution 3000 Temperature: 25 C 2500 Dynamic viscosity [mpas] Kollicoat IR PVA HPMC 3 type 603 HPMC 6 type Equipment: Haake Rotovisko RV1 Polymer concentration [%] Excipients make the difference F.Guth PharmSciFair
23 Dissolution of polymer films Modified dissolution tester Orifice (35x23 mm) Film Excipients make the difference F.Guth PharmSciFair
24 Solubility and dissolution of polymer films Time [s/100µm] HPMC type 603 HPMC type 606 PVA Kollicoat IR Beginning dissolution of the film Complete dissolution of the film Excipients make the difference F.Guth PharmSciFair
25 Elongation at break Texture Analyzer TA-XT2i HR Stable Micro Systems Excipients make the difference F.Guth PharmSciFair
26 Elongation at break Strain [N/mm²] Elongation at break [%] Kollicoat IR PVA HPMC 3 cp HPMC 6 cp Excipients make the difference F.Guth PharmSciFair
27 Applications Application Instant release coating Binder Pore former in sustained release applications API loaded films Film former in sprays Functionality Protects against unpleasant taste or odor Improves appearance Makes tablets easier to swallow Protects sensitive active ingredients For very rapidly dispersible/ soluble granules or tablets Highly flexible and hydrophilic pore former allows to adjust release rates Polymer carrier Extremely flexible texture Excipients make the difference F.Guth PharmSciFair
28 Novel excipients the regulatory challenge Novel excipients are very welcome at R&D departments,... Precedence of use Pharmacopoeia monograph..., but who wants to be the first to file a drug application? Generic companies in less regulated markets use novel products first Excipients make the difference F.Guth PharmSciFair
29 Kollicoat IR a commitment to innovation Product launch 1 st Approved drug product EU (Ger) Japan USA Draft Ph.Eur. Monograph PE 20/ 3 Draft NF. Monograph PF 35 (2) Today, Kollicoat IR is also approved and used in several other countries all over the world! Since 1998 BASF has sucessfully introduced 13 new excipients. Two of them were new chemical entities Excipients make the difference F.Guth PharmSciFair
30 Conclusion We believe that the challenges in drug delivery can only be overcome with new technologies and new excipients. New and highly functional excipients can help to reduce drug dosages, minimize side effects and therefore make medicines better and safer. New excipients can contribute to a cost effective and efficient manufacture of drug products and offer the possibility to differentiate. Excipients make the difference! Excipients make the difference F.Guth PharmSciFair
31 Thank you for your attention! Data: Dr. Karl Kolter, Nils Rottmann, Thorsten Cech Dr. Felicitas Guth Global Technical Service Excipients BASF SE G-EMP/ME Pharma Ingredients & Services Care Chemicals Phone: + 49 (0) 621 / Fax: + 49 (0) 621 / Mail: Internet: felicitas.guth@basf.com Excipients make the difference F.Guth PharmSciFair
New formulas for successful drug delivery Hot-melt extrusion for enhanced solubility and bioavailability
New formulas for successful drug delivery Hot-melt extrusion for enhanced solubility and bioavailability Andreas Gryczke, an enabler in excipients Pharma Ingredients & Services. Welcome to more opportunities.
More informationVIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies
VIVAPHARM PVP/VA Copovidone, Ph.Eur. USP/NF, JPE, E 1208, FCC The Ultimate Tablet Binder for All Processing Technologies Direct Compression Dry Granulation Hot Melt Extrusion Wet Granulation VIVAPHARM
More informationBioavailability enhancement of poorly soluble APIs. Enhanced solubilization out of solid glassy solutions prepared by Hot-Melt Extrusion
Pharma Ingredients & Services. Welcome to more opportunities. Custom Synthesis Excipients Active Ingredients ExActConcepts Example: Itraconazole Bioavailability enhancement of poorly soluble APIs Enhanced
More informationSoluplus The Solid Solution Opening New Doors in Solubilization.
Soluplus The Solid Solution Opening New Doors in Solubilization. Dr. Shaukat Ali, an enabler in excipients Pharma Ingredients & Services. Welcome to more opportunities. Custom Synthesis Excipients Active
More information4. Monitoring of dissolution induced changes in film coat
4. Monitoring of dissolution induced changes in film coat composition 4.1 Introduction As membrane controlled drug delivery coatings are subjected to changes in coating composition, it is necessary to
More informationKollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M. Super-disintegrants and dissolution enhancers.
Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M Super-disintegrants and dissolution enhancers. 2 The Preface New: 4 dimensions of Kollidon CL standard, fine (CL-F), superfine (CL-SF) and micronized
More informationWherever life takes you BASF excipients for orally disintegrating tablets make medication easy
Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy Dr. Philipp Hebestreit, an enabler in excipients Pharma Ingredients & Services. Welcome to more opportunities.
More informationCombining HME & Solubilization: Soluplus - The Solid Solution By: Hendrik Hardung, PhD; Dejan Djuric, PhD; and Shaukat Ali, PhD
Combining HME & Solubilization: Soluplus - The Solid Solution By: Hendrik Hardung, PhD; Dejan Djuric, PhD; and Shaukat Ali, PhD INTRODUCTION Drug solubilization has drawn attention in recent years because
More informationBiopharmaceutics Dosage form factors influencing bioavailability Lec:5
Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 09/01/2019
More informationANNEXURE -2. Excipients profiles of Compritol ATO 888, Gelucire 43/01, HPMC and PVP and have been described in the following section.
2. EXCIPIENTS PROFILES ANNEXURE -2 Excipients profiles of Compritol ATO 888, Gelucire 43/01, HPMC and PVP and have been described in the following section. 2.1. COMPRITOL 888 Non proprietary names BP:
More informationDow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow
Dow Wolff Cellulosics Pharmaceutical Excipients Using ingenuity and savvy to help design healthcare solutions TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow Enhancing
More informationKolliphor P Grades. Technical Information. Poloxamers for Pharmaceutical Use. = Registered trademark of BASF Poloxamers Ph. Eur.
Technical Information Kolliphor P Grades June 2013 Supersedes issue dated February 2013 03_111136e-03/Page 1 of 8 WF-No. 122937 = Registered trademark of BASF Poloxamers Ph. Eur., Poloxamer USP/NF Poloxamers
More informationKollicoat Smartseal 30 D Active Protection
Pharma Ingredients & Services. Welcome to more opportunities. Custom Synthesis Excipients Active Ingredients Kollicoat Smartseal 3 D Active Protection Breaking new ground in taste masking and moisture
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1 Introduction This is an application for a CHMP Scientific Opinion in accordance with Article 58 of Regulation (EC) No 726/2004, in the context of cooperation with the World Health
More informationEasy, fast and reliable!
Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. Tailormade formulated. s film coating products are one-step coating
More informationCritical material properties for the design of robust drug products : excipient functionality related characteristics
Critical material properties for the design of robust drug products : excipient functionality related characteristics Dr Liz Meehan, Pharmaceutical Development, Macclesfield UK 1 Excipients Definition
More informationLYCOAT. New solutions for Film Coating from Roquette. LYCOAT for quicker quality coating
LYCOAT New solutions for Film Coating from Roquette LYCOAT for quicker quality coating Roquette LYCOAT New solutions for Film Coating from Roquette LYCOAT New solutions for Film Coating Film coating, the
More informationEasy, fast and reliable!
Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. s film coating products are one-step coating systems for pharmaceutical
More informationSCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationWhy and how does a pharmaceutical company take the risk to use novel excipients?
Why and how does a pharmaceutical company take the risk to use novel excipients? M. Sherry Ku, Ph.D. CSO, Anchen Pharmaceuticals Irvine, CA Excipient Fest, May 5, 2010 Puerto Rico Global Excipient Acceptability
More informationDVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ
QbD Approach to Formulation of Hydrophilic Matrix Using Sample Kit of Hypromellose [Metolose SR] DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa,
More informationCo-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009
Co-Processed Excipients: Regulatory Challenges Carl Mroz Colorcon Limited June 2009 What is a Co-Processed excipient? Several types of excipient contain multiple components by design Use of processing
More informationVolker Bühler. Pharmaceutical Technology of BASF Excipients. Pharma Ingredients &Services. Welcome to more opportunities.
Volker Bühler Pharmaceutical Technology of BASF Excipients Pharma Ingredients &Services. Welcome to more opportunities. Volker Bühler Pharmaceutical Technology of BASF Excipients 3 rd revised edition June
More informationInnovations in Design: NIA-West. Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017
Innovations in Design: NIA-West Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017 1 Innovations in Design: How Do You Stand Out? If all other competitors are the same
More information(12) Patent Application Publication (10) Pub. No.: US 2003/ A1
US 2003.01.18647A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0118647 A1 Seth (43) Pub. Date: (54) EXTENDED RELEASE TABLET OF Publication Classification METFORMIN (51)
More informationContinuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016
Continuous Granulation Using a Twin-Screw Extruder Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016 What is a twin screw extruder and how to use it for continuous granulation? Dry feed:
More informationREVISION OF MONOGRAPH ON TABLETS. Tablets
March 2011 REVISION OF MONOGRAPH ON TABLETS Final text for addition to The International Pharmacopoeia This monograph was adopted by the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical
More informationCHAPTER-2 DRUG AND POLYMER PROFILES
57 CHAPTER-2 DRUG AND POLYMER PROFILES 58 2.1 DRUG PROFILES 2.1.1 Lamivudine (3TC) 85 US FDA approval date: November 1995 Structural formula of lamivudine Physicochemical properties of lamivudine 1. Description
More informationEUDRAGIT L 100 and EUDRAGIT S 100
Technical Information EUDRAGIT L 100 and EUDRAGIT S 100 Specification and Test Methods Ph. Eur. Methacrylic Acid - Methyl Methacrylate Copolymer (1:1) Methacrylic Acid - Methyl Methacrylate Copolymer (1:2)
More informationMETOLOSE: CONTENTS PAGE
METOLOSE: CONTENTS PAGE 2 Preface What is Metolose Substitution types Specifications 1) Available grades & viscosity 2) Nomenclature 3) Packaging Characteristics of Metolose Properties of Metolose 1) Powder
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationCONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications
Hypromellose CONTENTS PAGE 2 Preface Matrix system Selection of METOLOSE grades Specifications Properties Powder Solution Application Related Patents 3 4-5 6 8 10 13 14 17 Please note: The information
More informationENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE
PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES ENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE Kantilal B. Narkhede *1, R. B. Laware 2, Y. P.
More informationPharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency
Pharma & Food Solutions POLYOX TM Water Soluble Resins Combining Flexibility with Consistency POLYOX 9-13 POLYOX 9-13 POLYOX * are nonionic poly (ethylene oxide) polymers that meet all the specifications
More informationFunctional Excipients for Suppository Applications
Functional Excipients for Suppository Applications Skin Delivery Platform 2016 1 The Skin Delivery Platform Major areas of activity are in 4 pillars PLATFORM : SKIN DELIVERY Dermal Drug Delivery Mildness
More informationA FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS
Research Article A FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS K. P. R. Chowdary *, Tanniru Adinarayana, T. Vijay, Mercy. R. Prabhakhar
More informationwe ve got you covered pharmaceutical product and solution guide
we ve got you covered pharmaceutical product and solution guide 2 / we ve got you covered Helping to ensure the efficacy, integrity and usability of pharmaceutical formulations At Ashland, our number one
More informationIngredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose
1 Pharmaceutical industry borrowed ingredients from other industries Food Cosmetic Industrial Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work that has all changed
More informationEUDRAGIT E 100, EUDRAGIT E PO and
Technical Information EUDRAGIT E 100, and Specification and Test Methods Ph. Eur. USP/NF JPE Basic Butylated Methacrylate Copolymer Amino Methacrylate Copolymer - NF Aminoalkyl Methacrylate Copolymer E
More informationTablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good
TABLET PRODUCTİON Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good quality at high standards. Based on preformulation
More informationSuppository Chapter Content
10 min SUPPOSITORY Suppository Chapter Content 1. Suppositories and Factors Affecting Drug Absorption 2. Ideal Suppository and Different Types of Bases 3. Methods of Suppository Manufacturing Suppository
More informationSUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING
SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING Dr. Dieter Lubda MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany Agenda: Sustained release
More informationPharma Ingredients & Services. Ibuprofen. Technical Information. = Registered trademark of BASF group USP, Ph. Eur., JP
Technical Information Ibuprofen April 2010 Supersedes issue dated January 2010 03_030720e-10/Page 1 of 14 = Registered trademark of BASF group USP, Ph. Eur., JP Pharma Ingredients & Services 03_030720e-10
More information7. SUMMARY, CONCLUSION AND RECOMMENDATIONS
211 7. SUMMARY, CONCLUSION AND RECOMMENDATIONS Drug absorption from the gastro intestinal tract can be limited by various factors with the most common one being poor aqueous solubility and poor permeability
More informationFormulation Facilitation of Powder Blends, Sugar-Free Coatings and HME with an Unique Polyol
Formulation Facilitation of Powder Blends, Sugar-Free Coatings and HME with an Unique Polyol Presented by Bodo Fritzsching, BENEO-Palatinit GmbH at Excipient Fest Americas May 5th, 2010 The Ritz Carlton,
More informationFORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels
Seite 1 von 8 Share this story: Issue: April 2015, Posted Date: 3/30/2015 FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels INTRODUCTION Soft gelatin capsules (softgels) continue
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-8 Page 1 of 6 Are Cellulosic Controlled Release Technologies Vulnerable to Dose Dumping in Ethanolic Dissolution Media? Elanor Pinto,
More informationChallenges and solutions for moisture sensitive API formulation
Challenges and solutions for moisture sensitive API formulation Introduction Today, formulators are looking for alternative processes to reformulate existing products or to formulate New Chemical Entities
More informationUniversity of Sulaimani School of Pharmacy Dept. of Pharmaceutics Third level - Second semester
University of Sulaimani School of Pharmacy Dept. of Pharmaceutics Third level - Second semester 5/21/2017 Pharmaceutical Compounding, Dr. rer. nat. Rebaz Ali 1 Outlines Why rectal or vaginal route? Suppository
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Research Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com COMPARARISSION OF SOLUBILITY IMPROVEMENT OF CEFIXIME
More informationKURARAY POVAL & EXCEVAL
Characteristics Polyvinyl alcohol (PVOH) having varying degree of polymerization and. Recommended Uses Ranging from emulsion polymerization aid to binder for pigments in paper applications. Form supplied
More informationApplication of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products
57. Starch Convention, Detmold, April 26-28, 2006 K.-J. Steffens Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products Starches, Pharmaceutical Applications _ Starches
More informationFORMULATION AND CHARACTERIZATION OF TELMISATAN SOLID DISPERSIONS
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 974-434 Vol.2, No.1, pp 341-347, Jan-Mar 1 FORMULATION AND CHARACTERIZATION OF TELMISATAN SOLID DISPERSIONS Kothawade S. N. 1 *, Kadam
More informationExcipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical
Excipient Quality & Trouble Shooting By Seema Trivedi GM, Technical Back Ground The Society for Pharmaceutical Dissolution Science (SPDS) had held its 6th Annual International Convention Disso India -
More informationJournal of Pharmaceutical and Scientific Innovation
Journal of Pharmaceutical and Scientific Innovation www.jpsionline.com Research Article ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF ROSUVASTATIN BY USING SOLID DISPERSION TECHNIQUE Swathi T 1 *,
More informationLubriTose Mannitol Michael Crowley, Director of R&D, Excipients
LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2
More informationFormulation and Development of Sustained Release Tablets of Valsartan Sodium
INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Research Article Formulation and Development of Sustained Release Tablets of Valsartan Sodium G. Sandeep * and A. Navya Department of
More informationMylan Laboratories Limited F-4 & F-12, Malegaon MIDC, Sinnar Nashik Maharashtra State, India
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationANIMAL HEALTH DIVISION. Technologies & Services
ANIMAL HEALTH DIVISION Technologies & Services Friulchem AH division is a fully compliant with the EU cgmp. Since 2007, it is a dedicated finished product manufacturer and R&D service provider for the
More information1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small
Lecture-5 1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small intestine. Because the duodenum has the greatest
More informationGranulation Aggregation
Granulation Aggregation Wet granulation Solvent granulation (crust granules) Binder granulation (sticked granules) Granulation liquid Water Water + alcohol mixture Macromolecular colloidal solution i.e.:
More informationLIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)
November 2007 LIQUID PREPARATIONS FOR ORAL USE Final text for addition to The International Pharmacopoeia (November 2007) This monograph was adopted at the Forty-second WHO Expert Committee on Specifications
More informationHydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-069-1 (Supersedes PTR-069) Page 1 of 8 Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems
More informationAnyCoat. From Nature, Beside you.
AnyCoat From Nature, Beside you www.lotte-cellulose.com 04 AnyCoat is 05 Certificates of AnyCoat AnyCoat-C 06 General Characteristics 07 Specifications 08 Chemical Structure, Nomenclature 09 Functional
More informationFORMULATION AND EVALUATION OF VALSARTAN TABLETS EMPLOYING CYCLODEXTRIN-POLOXAMER 407-PVP K30 INCLUSION COMPLEXES
Int. J. Chem. Sci.: 10(1), 2012, 297-305 ISSN 0972-768X www.sadgurupublications.com FORMULATION AND EVALUATION OF VALSARTAN TABLETS EMPLOYING CYCLODEXTRIN-POLOXAMER 407-PVP K30 INCLUSION COMPLEXES K. P.
More informationComparative Evaluation of Enteric Film Coatings Applied in Organic Solvents
OPADRY Enteric Acryl-Based Coating System Poster Reprint Comparative Evaluation of Enteric Film Coatings Applied in Organic Solvents PURPOSE Delayed release (DR) film coated products are among the most
More informationLAB.2. Tablet Production Methods
LAB.2 Tablet Production Methods Dry methods Direct compression Dry granulation Wet methods Wet granulation Regardless whether tablets are made by direct compression or granulation, the first step, milling
More informationPublic Assessment Report. Scientific discussion. Pentasa Compact 4 g, prolonged-release granules. (mesalazine) NL License RVG:
Public Assessment Report Scientific discussion Pentasa Compact 4 g, prolonged-release granules (mesalazine) NL License RVG: 114015 Date: 30 March 2015 This module reflects the scientific discussion for
More informationFormulation and Evaluation of Gastroretentive Dosage form of Ciprofloxacin Hydrochloride.
Available online on www.ijcpr.com International Journal of Current Pharmaceutical Review and Research, 3(4), 105-109 Research Article ISSN: 0976-822X Formulation and Evaluation of Gastroretentive Dosage
More informationFROM SOLVENT TO AQUEOUS COATINGS. (Out of the Frying Pan...) Ralph E. Pondell. Coating Place, Inc. P.O. Box
84-1 FROM SOLVENT TO AQUEOUS COATINGS (Out of the Frying Pan...) Ralph E. Pondell Coating Place, Inc. P.O. Box 930310 Verona, WI 53593 A number of reasons exist for the current high level of interest in
More informationFolic Acid in Human Nutrition
Folic Acid in Human Nutrition Folic acid is a water soluble B vitamin widely distributed in foods. Deficiencies lead to impaired cell division and altered protein synthesis. Newborn children of women receiving
More informationskim milk as carrier by kneading method. They were evaluated for percentage yield, drug content, FT-IR
Available Online through ISSN: 0975-766X CODEN: IJPTFI Research Article www.ijptonline.com ENHANCEMENT OF SOLUBILITY & DISSOLUTION RATE OF LAMOTRIGINE BY KNEADING METHOD Gadhave M.V*, Mahakal A. J., Gaikwad
More informationSTABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS
Int. J. Chem. Sci.: 8(1), 2010, 405-414 STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS V. L. NARASAIAH, T. KARTHIK KUMAR, D. SRINIVAS, K. SOWMYA, P. L. PRAVALLIKA and Sk. Md. MOBEEN
More information(51) Int Cl.: A61K 9/14 ( ) A61K 31/5377 ( )
(19) TEPZZ 89 9_9A_T (11) EP 2 893 919 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication:.07. Bulletin /29 (1) Int Cl.: A61K 9/14 (06.01) A61K 31/377 (06.01) (21) Application number: 100064.7
More informationParenteral products-definition
Parenteral products-definition Parenteral preparations are sterile, pyrogen-free liquids (solutions, emulsions, or suspensions) or solid dosage forms packaged in either single-dose or multidose containers.
More informationLubricants for plastic processing licowax, Licolub, Licocene, licomont
Lubricants for plastic processing licowax, Licolub, Licocene, licomont Lubricants for plastic processing LICOWAX, LICOLUB, LICOCENE, LICOMONT Montan waxes For highly demanding plastic applications, our
More information>>> Oral Formulation Optimization. Introduction. A Tiered Approach for Identifying Enabling Formulations
Application Note #28-DMPK-3 >>> Oral Formulation Optimization Introduction Among the criteria required of compounds advancing from drug discovery programs, adequate systemic exposure (plasma concentrations
More informationSCIENTIFIC DISCUSSION. Darunavir
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical www.cirruspharm.com February 2014 INTRODUCTION Cirrus, a Kemwell company, is frequently
More informationFLORITER. New Technology for Innovative Formulation Design.
FLORITER New Technology for Innovative Formulation Design www.tomitaph.co.jp FLORITE Dramatically Change Your Formulation FLORITE is synthetic Calcium Silicate with exceptional liquid absorbency and excellent
More informationInternational Journal of Innovative Pharmaceutical Sciences and Research
International Journal of Innovative Pharmaceutical Sciences and Research www.ijipsr.com ENHANCEMENT OF SOLUBILITY OF RITONAVIR BY USING SOLID DISPERSION TECHNIQUE 1 K.Sai Saran*, 2 M.Srujan Kumar, 3 Dr.K.V.Subrahmanyam
More informationEXCIPIENTS FOR PHARMACEUTICALS
EXCIPIENTS FOR PHARMACEUTICALS SCOPE OF APPLICATION IOI Oleo GmbH PHARMA Contents Regulatory background for the IOI Oleo site in Witten: Regulatory background for the IOI Oleo site in Witten... 3 Injectables
More informationCAPMUL + CAPTEX + ACCONON = SEDDS
OUR SOLUTIONS PORTFOLIO ABITEC products are specifically designed for meeting the solubility challenges of the pharmaceutical industry. Our products can be used alone or in conjunction with one another
More informationOptimization of valsartan tablet formulation by 2 3 factorial design
Research Article ISSN: 0974-6943 K. P. R. Chowdary et al. / Journal of Pharmacy Research 2014,8(9, Available online through http://jprsolutions.info Optimization of valsartan tablet formulation by 2 3
More informationFORMULATION AND EVALUATION OF ETORICOXIB TABLETS EMPLOYING CYCLODEXTRIN- POLOXAMER PVPK30 INCLUSION COMPLEXES
Volume: 2: Issue-4: Oct - Dec -2011 ISSN 0976-4550 FORMULATION AND EVALUATION OF ETORICOXIB TABLETS EMPLOYING CYCLODEXTRIN- POLOXAMER 407 - PVPK30 INCLUSION COMPLEXES K.P.R. Chowdary*, K. Surya Prakasa
More informationPublic Assessment Report Scientific discussion. Doxazosin NM Pharma 4 mg prolonged-release tablet (Doxazosin mesilate) SE/H/465/01
Public Assessment Report Scientific discussion Doxazosin NM Pharma 4 mg prolonged-release tablet (Doxazosin mesilate) SE/H/465/01 This module reflects the scientific discussion for the approval of Doxazosin
More informationFORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS
International Journal of PharmTech Research CODEN( USA): IJPRIF ISSN : 0974-4304 Vol.1, No.3, pp 634-638, July-Sept 2009 FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS K. Reeta Vijaya
More informationSTUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS
Int. J. Chem. Sci.: 10(4), 2012, 1934-1942 ISSN 0972-768X www.sadgurupublications.com STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS K. VENUGOPAL * and K. P. R. CHOWDARY a Nirmala College
More informationPatel B et al. IRJP 1 (1)
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY Available online http://www.irjponline.com Research Article IMPROVEMENT OF SOLUBILITY OF CINNARIZINE BY USING SOLID DISPERSION TECHNIQUE Patel Bipin*, Patel Jayvadan,
More informationCHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION
CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION LEARNING OBJECTIVES The objectives of this unit are to: Understand the formulation of solid dosage form. Understand the characteristic
More informationDEVELOPMENT OF NON SODIUM EFFERVESCENT TABLET OF PARACETAMOL USING ARGININE CARBONATE
IJPSR (2013), Vol. 4, Issue 5 (Research Article) Received on 17 July, 2012; received in revised form, 23 February, 2013; accepted, 14 April, 2013 DEVELOPMENT OF NON SODIUM EFFERVESCENT TABLET OF PARACETAMOL
More informationDissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1
Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1 ASAHI KASEI CHEMICALS CORPORATION CEOLUS R&D DEPARTMENT 1 CONTENTS General
More informationExcipient Considerations for Continuous Manufacturing Implementation
Excipient Considerations for Continuous Manufacturing Implementation FDA-PQRI Conference March 22-24, 2017 David R. Schoneker Director of Global Regulatory Affairs Email: dschoneker@colorcon.com 1 Continuous
More informationAnimal Health. Premixes Dietary Fibers. and Gels Solid. Dosage Forms. Liquids. Product Overview. Customize Your Formulation
Animal Health Product Overview Liquids and Gels Solid Dosage Forms Premixes Dietary Fibers Customize Your Formulation ANIMAL HEALTH Product Overview General Information Liquids and Gels Healthcare is essential
More informationPublic Assessment Report. Scientific discussion. Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets.
Public Assessment Report Scientific discussion Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets (tadalafil) NL/H/3634/001-004/DC Date: 24 May 2017 This module reflects the scientific
More information(Non-legislative acts) REGULATIONS
29.8.2013 Official Journal of the European Union L 230/1 II (Non-legislative acts) REGULATIONS COMMISSION REGULATION (EU) No 816/2013 of 28 August 2013 amending Annex II to Regulation (EC) No 1333/2008
More informationIon Exchange Resins. Unique Solutions to Formulation Problems
Ion Exchange Resins Unique Solutions to Formulation Problems Lyn Hughes Some of the common problems faced by formulators and how using ion exchange resins may be able to solve them are discussed. PHOTODISC,
More informationSUMMARY AND CONCLUSION
SUMMARY AND CONCLUSION 8 SUMMARY AND CONCLUSIONS In spite of the many challenges faced by researchers while designing an effective, reproducible and stable dosage form, oral dosage forms continued to maintain
More informationExcipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015
Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015 Dr. Susanne Keitel Director EDQM, Council of Europe Outline 1. The European Pharmacopoeia 2. The importance of
More informationPublic Assessment Report Scientific discussion. Ciprofloxacin Accord (ciprofloxacin hydrochloride) SE/H/1026/01-03/DC
Public Assessment Report Scientific discussion Ciprofloxacin Accord (ciprofloxacin hydrochloride) SE/H/1026/01-03/DC This module reflects the scientific discussion for the approval of Ciprofloxacin Accord.
More information